MS Australia’s 2026 Major Grants Round is funding a diverse range of MS research across Australia, advancing our quest to prevent, treat, and ultimately cure MS.
Australian researchers can study more than 100 genetic risk factors for MS together, a breakthrough that brings scientists closer to understanding how the disease develops and to improving quality of life for people living with MS.
CEO Rohan Greenland previews next week’s Parliamentary Friends of MS event at Parliament House, announcing new MSA grants, celebrating researchers, and calling for stronger government investment in medical research.
New data shows fenebrutinib delays disability progression in primary progressive MS, especially preserving arm function, with a comparable safety profile to ocrelizumab.
A new Australian study found pain is more common in people with MS than in the general population. It describes the lived experience of different types of pain and how they occur in different proportions and severity and differ by MS type, guiding towards better management.
CEO Rohan Greenland says to hold on to your hats, because 2026 is going to be another big year for the MS community, not only here in Australia, but across the world.
The phase 3 clinical trial of tolebrutinib did not delay disability progression in people with primary progressive MS, and it has not been approved in the USA for non-relapsing secondary progressive MS.
The Federal Government announced on 8 Jan 2026 that ublituximab (Briumvi®) has been listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsing remitting MS.
ANZgene researchers analysed genetic data from thousands of people with and without MS to see if rare changes in other disease genes affect MS risk or severity.
